Novartis tosses more US PD-1 submission plans and another anti-CD40 drug indication
Buried in Novartis’ third quarter report were a few key indication drops.
First, Novartis is no longer planning to submit tislelizumab for FDA approval in first-line nasopharyngeal cancer or first-line non-small cell lung cancer alongside chemotherapy — marking two more US regulatory setbacks for the PD-1 checkpoint inhibitor for which Novartis gave BeiGene $650 million for US and ex-China rights.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.